公开(公告)号：EP4488345A1

公开(公告)日：2025-01-08

申请号：EP23763563.6

申请日：2023-03-02

Applicant: OSAKA UNIVERSITY ,  Oxide Corporation

Inventor： MINEMOTO, Hisashi ,  HIGASHIKAWA, Masahiro ,  FUJIOKA, Kana ,  FUJI, Hiroshi ,  YAMAMOTO, Kazuhisa ,  KUSUNOKI, Tsuneo ,  TOKUMITSU, Seika ,  KAWABE, Hideo

IPC: C09K11/55 ,  C09K11/59 ,  C09K11/64

Abstract: Composite ceramic (1) is composed of a sintered body containing a garnet-based phosphor component (2), a nitride-based phosphor component (3), and a matrix component (4) that is at least one selected from the group consisting of MgO and Al 2 O 3 , the matrix component having a content of not less than 31 wt% and not more than 95 wt% of all components of the composite ceramic (1), and the matrix component being sintered so as to surround the garnet-based phosphor component and the nitride-based phosphor component.

公开(公告)号：EP4477744A1

公开(公告)日：2024-12-18

申请号：EP23749881.1

申请日：2023-02-06

Applicant: OSAKA UNIVERSITY

Inventor： KINOOKA, Masahiro ,  KIM, Meehae ,  FUJINAGA, Yukako

IPC: C12N5/071 ,  C07K14/33

Abstract: A method for producing a retinal pigment epithelial (RPE) cell, including promoting differentiation induction from a pluripotent stem cell into an RPE cell by culturing the pluripotent stem cell in a medium containing an E-cadherin inhibitor is provided by the present invention.

公开(公告)号：EP4477743A1

公开(公告)日：2024-12-18

申请号：EP23749882.9

申请日：2023-02-06

Applicant: OSAKA UNIVERSITY

Inventor： KINOOKA, Masahiro ,  KIM, Meehae ,  FUJINAGA, Yukako

IPC: C12N5/02 ,  C12N5/0735 ,  C12N5/10

Abstract: The present invention provides an agent for directional control of differentiation induction of a pluripotent stem cell, comprising an E-cadherin inhibitor.

公开(公告)号：EP4467646A1

公开(公告)日：2024-11-27

申请号：EP23743341.2

申请日：2023-01-20

Applicant: OSAKA UNIVERSITY ,  Stemrim Inc.

Inventor： TAMAI, Katsuto ,  KIKUCHI, Yasushi ,  TAMAKOSHI, Tomoki ,  YAMAZAKI, Takehiko

IPC: C12N15/12 ,  A61K35/36 ,  A61L27/38 ,  A61L27/50 ,  A61L27/60 ,  A61P17/04 ,  C12N5/071 ,  C12N5/10 ,  C12N15/63 ,  C12N15/867

Abstract: The present disclosure relates to a cell sheet for transplantation onto the skin of a patient with dystrophic epidermolysis bullosa. The cell sheet is composed of cells which are obtained from a body fluid within a blister of a patient with dystrophic epidermolysis bullosa. A type VII collagen gene is introduced into the cells.

公开(公告)号：EP4461807A1

公开(公告)日：2024-11-13

申请号：EP23740320.9

申请日：2023-01-13

Applicant: OSAKA UNIVERSITY ,  Terumo Kabushiki Kaisha

Inventor： EGUCHI, Hidetoshi ,  TOMIMARU, Yoshito ,  MIYAGAWA, Shigeru ,  TOYA, Keisuke ,  OHASHI, Fumiya

IPC: C12N5/077 ,  A61K35/34 ,  A61L27/38 ,  A61L27/44 ,  A61P1/16 ,  A61P35/00 ,  C12N15/09

Abstract: [Problem]
It is an object of the present invention to provide a means for treating liver dysfunction.
[Solution]
The above object was achieved by providing a sheet-shaped cell culture containing skeletal myoblasts for treating liver dysfunction or improving liver function; a method for producing the sheet-shaped cell culture, including a step of seeding a cell population containing skeletal myoblasts on a culture substrate, a step of forming a sheet of the cell population into a sheet to form a sheet-shaped cell culture, and a step of detaching the formed sheet-shaped cell culture from the culture substrate; and a method for treating liver dysfunction, including a step of applying the sheet-shaped cell culture to a site exhibiting the liver dysfunction.

公开(公告)号：EP4454663A1

公开(公告)日：2024-10-30

申请号：EP22911314.7

申请日：2022-12-21

Applicant: The University of Tokyo ,  OSAKA UNIVERSITY

Inventor： NOMURA, Seitaro ,  KO, Toshiyuki ,  KATOH, Manami ,  ABURATANI, Hiroyuki ,  KOMURO, Issei ,  NAKAGAMI, Hironori

IPC: A61K39/395 ,  A61P9/04 ,  A61P9/10 ,  A61K38/48 ,  G01N33/53 ,  A01K67/027 ,  A61K31/7088

Abstract: An object of the present invention is to provide a therapeutic or preventive agent for myocardial infarction, cardiac fibrosis, or heart failure using Htra3 as a therapeutic target. According to the present invention, there is provided a therapeutic or preventive agent for myocardial infarction, cardiac fibrosis, or heart failure containing at least one of (a) serine protease HtrA3, (b) a nucleic acid encoding HtrA3, (c) an expression vector containing a nucleic acid encoding HtrA3, (d) a cell transformed with the nucleic acid or the expression vector, and (e) an antibody that binds to serine protease HtrA3.

公开(公告)号：EP4454649A1

公开(公告)日：2024-10-30

申请号：EP22911253.7

申请日：2022-12-21

Applicant: OSAKA UNIVERSITY ,  Shionogi & Co., Ltd

Inventor： AGO Yukio ,  YAMAKAWA Hidekuni ,  NAKAMURA Atsushi

IPC: A61K31/485 ,  A61P25/18

Abstract: Provided are a new pharmaceutical composition and a method for treating and/or preventing autism spectrum disorder, fragile X syndrome, and/or an autism spectrum disorder-like symptom. A pharmaceutical composition for the treatment and/or prevention of autism spectrum disorder, fragile X syndrome, and/or an autism spectrum disorder-like symptom, comprising buprenorphine or a pharmaceutically acceptable salt thereof and/or morphine or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP4438048A1

公开(公告)日：2024-10-02

申请号：EP22898585.9

申请日：2022-11-22

Applicant: Regcell Co., Ltd. ,  OSAKA UNIVERSITY

Inventor： MIKAMI, Norihisa ,  SAKAGUCHI, Shimon

IPC: A61K35/17 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/06 ,  A61P9/00 ,  A61P9/14 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P25/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02

CPC classification number: A61K35/17 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P5/16 ,  A61P7/06 ,  A61P9/14 ,  A61P13/12 ,  A61P9/00 ,  A61P17/06 ,  A61P19/02 ,  A61P15/00 ,  A61P25/00 ,  A61P25/02 ,  A61P21/00 ,  A61P21/04 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  C07K14/55 ,  C12N1/00 ,  C12N5/06 ,  C12Q1/02

Abstract: According to the present disclosure, there is provided a pharmaceutical composition for treating or preventing a T cell-related disorder, the pharmaceutical composition comprising an inducible regulatory T cell having high functionality and stable immunosuppressive function. T cell : The present disclosure provides a pharmaceutical composition for treating or preventing a T cell-related disorder, the pharmaceutical composition comprising, as an active ingredient, an inducible regulatory T cell having at least one feature selected from the group consisting of CTLA4 positivity, NT5E positivity, ITGAE (CD103) positivity, and AREG positivity.

公开(公告)号：EP4424441A1

公开(公告)日：2024-09-04

申请号：EP22886907.9

申请日：2022-10-21

Applicant: Toppan Holdings Inc. ,  OSAKA UNIVERSITY

Inventor： SEKIGUCHI, Takuya ,  CHEN, Chuantong ,  SUGANUMA, Katsuaki

IPC: B22F7/08 ,  B22F1/00 ,  B22F9/00 ,  H01L21/52

CPC classification number: B22F1/00 ,  B22F7/08 ,  B22F9/00 ,  H01L21/52

Abstract: A sintered material containing silver particles, copper particles, a nitrogen-containing compound, and a reducing agent, in which a primary particle diameter of the silver particles is 200 nm or less, and a volume-based 50% cumulative particle diameter of the copper particles, as measured by laser diffraction/scattering particle diameter distribution measurement, is 1 µm or more.

公开(公告)号：EP4410302A1

公开(公告)日：2024-08-07

申请号：EP22876529.3

申请日：2022-09-30

Applicant: OSAKA UNIVERSITY ,  Niigata University ,  Stemrim Inc.

Inventor： SHIMBO, Takashi ,  TERAI, Shuji ,  TSUCHIYA, Atsunori ,  YAMAZAKI, Takehiko ,  TAMAI, Katsuto.

IPC: A61K38/17 ,  A61P1/16

CPC classification number: A61K38/17 ,  A61P1/16

Abstract: The present inventors have discovered that a peptide derived from HMGB 1 can be used as a therapeutic and/or preventive agent for fatty liver, nonalcoholic steatohepatitis, and various symptoms accompanied by the fatty liver. On the basis of this discovery, the present application provides a use of the peptide derived from HMGB 1 which is different from conventional uses.